Immune Dysregulation Panel
Use
This test is designed for individuals exhibiting symptoms or having a clinical or suspected diagnosis of immune dysregulation disorders. It is also suitable for individuals with a family history of familial hemophagocytic lymphohistiocytosis (FHL) or autoimmune lymphoproliferative syndrome (ALPS), which are indicative of immune dysregulation. The panel provides valuable insights into genetic mutations that may contribute to such conditions, aiding in diagnosis and guiding treatment decisions.
Special Instructions
Not provided.
Limitations
The test is primarily based on NGS with CNV analysis using Exome or Genome Platforms. DNA obtained from various specimen types is required for accurate results. The test does not have FDA approval and should be interpreted in the context of additional clinical findings. Testing is conducted following CAP and CLIA regulations, but it has not received FDA clearance or approval.
New York Approved
Methodology
NGS (Targeted)
Biomarkers
59 genes
Gene
Result Turnaround Time
14-21 days
Related Documents
For more information, please review the documents below
Specimen
Whole Blood
Volume
Not provided
Minimum Volume
Not provided